The World Market for Infectious Disease Diagnostic Tests

Attention: There is an updated edition available for this report.
   Single User - $3,995
   Site License (one location, 10 users) - $5,995
   Corporate License - $7,990

Published Oct 21, 2013 | 532 Pages | Pub ID: KLI5137619

Infectious diseases are among the most challenging issues facing health care delivery systems around the world today. The World Health Organisation estimates that more than 17 million people die of an infectious disease each year, with many of these acquired in hospitals. This Kalorama Information report, The World Market for Infectious Disease Diagnostic Tests, takes a comprehensive look at the markets for companies of testing products that can combat infectious disease threats. 

One of the Most Dynamic Areas of the IVD Market, Comprehensively Covered

The art of microorganism identification and therapy decisions is becoming increasingly more important and more complex. This provides both challenges and opportunities for infectious disease testing. The world is getting smaller and smaller - people and products are moving over country boundaries as never before. Immigrants and visitors to countries bring with them different species of microorganisms that may require identification. Therefore highly sophisticated and versatile methodologies are required to respond for the need to identify a larger and more diversified list of pathogens. The report provides a review of trends and technological advancements in infectious disease testing in the next 5 years.

Market Size and Sales Forecasts to 2017 by Type of Test

Sales and forecasts of infectious disease reagents are made through to 2017. Emerging products and markets are described; key players and strategies discussed and competitive trends are analyzed. Specific market details are provided for the following:

  • HIV Testing, Molecular and Immunoassays
  • Respiratory Infecton Testing
  • Immunoassays for STDs
  • Immunoassays for Hepatitis
  • TORCH testing
  • Rapid Influenza Testing
  • Rapid Malaria Testing
  • Rapid HIV
  • Rapid Strep A
  • Rapid Hepatitis,
  • Rapid STD Testing
  • C. diff Testing
  • E. coli Testing
  • H. pylori Testing
  • OTC - Home Use Testing For Infectious Disease
  • Molecular HIV Testing
  • Molecular Hepatitis Testing
  • Molecular GC/Chlamydia Testing
  • Molecular Hospital Acquired Infection Testing
  • Molecular Respiratory Testing
  • Organism ID Testing
  • Blood Bank, Immunoassays
  • Blood Bank, Molecular
  • ID/AST Panels
  • ID/AST Chromogenetic Media
  • Parasitology
  • Sepsis Testing
  • Others

Market analysis in this report covers world markets for infectious disease tests, however the reader will find a bias toward the developed areas of the globe -- North America, Japan and Western Europe. The BRIC set of countries (Brazil, Russia, India and China) have drawn a lot of attention in the economic media in the past 2 -3 years. Thus there is more discussion of the mix of economics and diagnostics that may evolve in these countries. Nevertheless, infectious diseases are a growing global problem and where possible the report covers IVD products related to the globalization of diseases.

All market data are based on factory sales to the end user and not retail pricing or reimbursement payments. Data for the in vitro diagnostic market are presented in U.S. dollar market size for categories of tests, and for specific analytes where possible. The dollar value of a market segment is directly proportional to the number of tests performed, because the cost of the instrumentation is generally buried in the per test price.

The Threat of Emerging Infectious Disease

Globalization has made the world a smaller place in a very short time. There are numerous reports of the spread of imported diseases such a lyme, chagas and malaria to regions where they were not usually present. Global travel and trade, along with climate change, are expanding the habitats of the mosquitoes that carry many of the vector-borne infectious disease far and wide.

Thus not only is it imperative to have rapid and efficient tests for countries in the developing world, healthcare providers in developed countries can also benefit. The situation in developed countries is probably less urgent for the tropical diseases, but it is equally important to have better rapid tests for hepatitis, HIV, tuberculosis and sexually transmissible diseases worldwide. The following diseases are covered in the report in detail.

  • Chagas Disease
  • Chikungunya
  • Dengue
  • HIV
  • HPV/ cervical cancer
  • Respiratory
  • Hepatitis
  • HAIs
  • Diarrheal Diseases
  • Leishmaniasis
  • Leptospirosis
  • Malaria
  • Onchocerciasis
  • STDs
  • TB

For each of these diseases, the report provides statistics, and an estimate of the opportunity for IVD companies.

The report discusses tests and technologies that are currently available and those that are expected to take their place. Generally, current products and technologies establish the standard of care and its value to payers. Many of the assays and techniques presented in the report are expected to replace the standard of care in 2012, but with healthcare systems’ emphasis on cost/benefit analysis for new technologies adoption, the market value and thus penetration capabilities of newer approaches may be limited.

Exhaustive Company Profiling

The information contained in this report has been assembled from primary and secondary data. Secondary date was collected from peer review journals and industry generated press releases. Primary research was conducted via telephone conversation with selected diagnostic marketers of in vitro diagnostics to assess the current market and trends in laboratory medicine.

  • Abbott Diagnostics
  • Beckman Coulter Inc./Danaher
  • Becton, Dickinson and Company (BD)
  • BD GeneOhm
  • bioMérieux Inc. Marcy L'etoile, France Www.Biomerieux.Com
  • Bio-Rad Laboratories Inc.
  • Gen-Probe Inc.
  • Hologic, Inc.
  • Ortho Clinical Diagnostics
  • Roche Diagnostics
  • Siemens Healthcare Diagnostics
  • Thermo Fisher Scientific Inc.
  • Bruker BioSciences Corporation
  • CHROMagar
  • Copan Diagnostics Inc.
  • Hardy Diagnostics
  • Laboratorios CONDA
  • Lab M
  • Liofilchem S.R.L.
  • Mindray Bio-Medical Electronics Co., Ltd
  • Oxoid
  • Serosep Limited
  • Astra Biotech GmbH
  • Cavidi AB
  • Cellestis Ltd
  • Corgenix Medical Corporation
  • Diagnostic HYBRIDS, Inc. (DHI)
  • DiaSorin S.p.A
  • Diaxonhit
  • Euroimmun AG
  • Fujirebio Diagnostics, Inc.
  • Gold Standard Diagnostics
  • Immunetics Inc.
  • Immuno-Mycologics (IMMY)
  • InBios International, Inc.
  • Luminex Corporation
  • MBio Diagnostics, Inc.
  • Meridian Bioscience, Inc.
  • illumigene Molecular
  • Meridian Life Science
  • J.Mitra & Co. Pvt Ltd
  • MP Biomedicals LLC
  • Nova Biomedical
  • OncoHealth Corporation
  • Orgentec Diagnostika
  • Oxford Immunotec Ltd.
  • Pro-Lab Diagnostics
  • Quanterix Corporation
  • Quidel Corporation
  • Sekisui Diagnostics (formerly Genzyme Diagnostics)
  • TECHLAB Inc.
  • Trinity Biotech plc
  • The Tulip Group
  • Vircell, SL
And Many Other Companies in Infectious Disease Diagnostic Testing…
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times